0102030405
Saxagliptin CAS No. 361442-04-8 Pharmaceutical Raw Material
02
introduce
introduce
Saxagliptin is a potent oral dipeptidyl peptidase 4 (DPP-4) inhibitor and core antidiabetic API. It selectively inhibits DPP-4 enzyme, prolonging the half-life of endogenously produced GLP-1 and GIP (incretins) to regulate blood glucose, approved for Type 2 Diabetes Mellitus (T2DM) treatment.
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply for clinical use and pharmaceutical formulation.
02
Physical and chemical properties
Saxagliptin exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Density: 1.35 g/cm³
- Melting Point: 103-107 °C
- Boiling Point: 548.7±35.0 °C
- Flash Point: 548.7℃
- Storage: Sealed in dry, 2-8°C
- Stability: Temperature Sensitive
- Solubility: Slightly soluble in DMSO and methanol
- Density: 1.35 g/cm³
- Melting Point: 103-107 °C
- Boiling Point: 548.7±35.0 °C
- Flash Point: 548.7℃
- Storage: Sealed in dry, 2-8°C
- Stability: Temperature Sensitive
- Solubility: Slightly soluble in DMSO and methanol
1. Precise Hypoglycemic Mechanism
As a dipeptidyl peptidase-4 (DPP-4) inhibitor, it exerts its effect by inhibiting the degradation of incretin hormones (e.g., GLP-1), regulates insulin secretion and improves peripheral tissue glucose utilization in a glucose-dependent manner, only taking effect when blood glucose rises. It has a lower probability of causing hypoglycemia and better medication safety.
As a dipeptidyl peptidase-4 (DPP-4) inhibitor, it exerts its effect by inhibiting the degradation of incretin hormones (e.g., GLP-1), regulates insulin secretion and improves peripheral tissue glucose utilization in a glucose-dependent manner, only taking effect when blood glucose rises. It has a lower probability of causing hypoglycemia and better medication safety.
2. Strong Combination Compatibility
It can be used alone to improve blood glucose control, or combined with various hypoglycemic drugs such as metformin, sulfonylureas and thiazolidinediones to enhance the overall hypoglycemic efficacy.
It can be used alone to improve blood glucose control, or combined with various hypoglycemic drugs such as metformin, sulfonylureas and thiazolidinediones to enhance the overall hypoglycemic efficacy.
3. Good Tolerability
Unlike some hypoglycemic drugs that can cause weight gain (e.g., sulfonylureas), saxagliptin does not lead to weight increase, making it more suitable for patients with type 2 diabetes complicated with overweight or obesity.
1. Metabolic Disease Treatment
(1) Monotherapy for Type 2 Diabetes Mellitus (T2DM) in adults to improve glycemic control.
(2) Combination therapy with metformin, sulfonylureas, or thiazolidinediones for T2DM patients with inadequate glucose control.
2. Biomedical Research
Tool compound for studying DPP-4/incretin signaling pathways and development of novel antidiabetic therapies.
(1) Monotherapy for Type 2 Diabetes Mellitus (T2DM) in adults to improve glycemic control.
(2) Combination therapy with metformin, sulfonylureas, or thiazolidinediones for T2DM patients with inadequate glucose control.
2. Biomedical Research
Tool compound for studying DPP-4/incretin signaling pathways and development of novel antidiabetic therapies.
We implement strict full-process quality control, with each batch of Saxagliptin undergoing rigorous testing of key indicators including purity , solubility, stability, chiral purity, and impurity content to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and production needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and production needs.
As a well-established DPP-4 inhibitor, Saxagliptin is a cornerstone in Type 2 Diabetes Mellitus treatment, offering safe, convenient, and glucose-dependent glycemic control. With its proven clinical efficacy, favorable safety profile, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Saxagliptin API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Saxagliptin to meet your needs in pharmaceutical formulation, antidiabetic research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Saxagliptin to meet your needs in pharmaceutical formulation, antidiabetic research, and clinical treatment. Contact us for more product details and cooperation support.